A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)

Overview of attention for article published in BMC Cancer, March 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

policy: 1 policy source

twitter: 42 X users

Citations

dimensions_citation: 34 Dimensions

Readers on

mendeley: 109 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 20 Jun 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.